1
|
Mori T, Abe I. Lincosamide Antibiotics: Structure, Activity, and Biosynthesis. Chembiochem 2024; 25:e202300840. [PMID: 38165257 DOI: 10.1002/cbic.202300840] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2023] [Revised: 12/29/2023] [Accepted: 01/02/2024] [Indexed: 01/03/2024]
Abstract
Lincosamides are naturally occurring antibiotics isolated from Streptomyces sp. Currently, lincomycin A and its semisynthetic analogue clindamycin are used as clinical drugs. Due to their unique structures and remarkable biological activities, derivatizations of lincosamides via semi-synthesis and biosynthetic studies have been reported. This review summarizes the structures and biological activities of lincosamides, and the recent studies of lincosamide biosynthetic enzymes.
Collapse
Grants
- JP20H00490 Ministry of Education, Culture, Sports, Science and Technology, Japan
- JP22H05126 Ministry of Education, Culture, Sports, Science and Technology, Japan
- JP23H00393 Ministry of Education, Culture, Sports, Science and Technology, Japan
- JP23H02641 Ministry of Education, Culture, Sports, Science and Technology, Japan
- JPNP20011 New Energy and Industrial Technology Development Organization
- JP21ak0101164 New Energy and Industrial Technology Development Organization
- JP23ama121027 New Energy and Industrial Technology Development Organization
- JPMJPR20DA Japan Science and Technology Agency
Collapse
Affiliation(s)
- Takahiro Mori
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan
- Collaborative Research Institute for Innovative Microbiology, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan
- PRESTO, Japan Science and Technology Agency, 4-1-8, Honcho, Kawaguchi, Saitama, 332-0012, Japan
| | - Ikuro Abe
- Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan
- Collaborative Research Institute for Innovative Microbiology, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo, 113-8657, Japan
| |
Collapse
|
2
|
Kumura K, Umemura E, Hirai Y, Ajito K. Discovery of Novel Lincomycin Derivatives Effective against Resistant Streptococcus pneumoniae and Streptococcus pyogenes Possessing ErmB Gene. J SYN ORG CHEM JPN 2022. [DOI: 10.5059/yukigoseikyokaishi.80.676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Ko Kumura
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd
| | | | | | | |
Collapse
|
3
|
Hirai Y, Maebashi K, Yamada K, Wakiyama Y, Kumura K, Umemura E, Ajito K. Characterization of compound A, a novel lincomycin derivative active against methicillin-resistant Staphylococcus aureus. J Antibiot (Tokyo) 2020; 74:124-132. [PMID: 33060814 DOI: 10.1038/s41429-020-00375-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Revised: 09/11/2020] [Accepted: 09/13/2020] [Indexed: 11/09/2022]
Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is one of causative bacteria for hospital- and community-acquired infections. In order to overcome MRSA infection, we synthesized compound A, a lincomycin derivative, and evaluated the biological properties. The MIC50 and MIC90 values of compound A against MRSA clinical isolates, which were susceptible to clindamycin, from infected skin in Japan were 0.12 and 0.25 μg ml-1, respectively, and those against hospital-acquired MRSA with clindamycin resistance were 1.0 and 2.0 μg ml-1, respectively. Linezolid non-susceptible MRSA selected in the laboratory had mutations in the 23S rRNA gene and exhibited cross-resistance to compound A. MRSA non-susceptible to compound A selected in laboratory was not cross-resistant to linezolid, implying that the binding site to 23S rRNA partly overlaps with clindamycin and linezolid. The in vivo efficacies of compound A against mouse skin abscess model infected with clindamycin-susceptible and -resistant MRSA were superior to those of clindamycin and linezolid, respectively. The well-known linezolid-induced myelosuppression is caused by its inhibitory effect on mitochondrial function, but inhibition was weaker for compound A than that of linezolid. In short, compound A has broader anti-MRSA activities than clindamycin and linezolid due to additional binding site, and demonstrated preferable safety profile as a potential anti-MRSA drug.
Collapse
Affiliation(s)
- Yoko Hirai
- Pharmacology Research Laboratory, Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan. .,Licensing and Product Acquisition, Partnering Strategy and Business Development Department, Meiji Seika Pharma Co., Ltd., Tokyo, Japan.
| | - Kazunori Maebashi
- Pharmacology Research Laboratory, Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan.,Drug Development Planning and Management Group, R&D Planning and Management, Meiji Seika Pharma Co., Ltd., Tokyo, Japan
| | - Keiko Yamada
- Pharmacology Research Laboratory, Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan
| | - Yoshinari Wakiyama
- Medical Chemistry Laboratory, Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan
| | - Ko Kumura
- Medical Chemistry Laboratory, Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan
| | - Eijiro Umemura
- Medical Chemistry Laboratory, Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan.,Laboratory of Medicinal Chemistry, Institute of Microbial Chemistry, Tokyo, Japan
| | - Keiichi Ajito
- Medical Chemistry Laboratory, Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd., Yokohama, Japan.,Kitasato Research Center for Environmental Science, Sagamihara, Japan
| |
Collapse
|
4
|
Maji M, Chakrabarti K, Paul B, Roy BC, Kundu S. Ruthenium(II)-NNN-Pincer-Complex-Catalyzed Reactions Between Various Alcohols and Amines for Sustainable C−N and C−C Bond Formation. Adv Synth Catal 2017. [DOI: 10.1002/adsc.201701117] [Citation(s) in RCA: 86] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Milan Maji
- Department of Chemistry; Indian Institute of Technology Kanpur; Kanpur - 208016 India
| | - Kaushik Chakrabarti
- Department of Chemistry; Indian Institute of Technology Kanpur; Kanpur - 208016 India
| | - Bhaskar Paul
- Department of Chemistry; Indian Institute of Technology Kanpur; Kanpur - 208016 India
| | - Bivas Chandra Roy
- Department of Chemistry; Indian Institute of Technology Kanpur; Kanpur - 208016 India
| | - Sabuj Kundu
- Department of Chemistry; Indian Institute of Technology Kanpur; Kanpur - 208016 India
| |
Collapse
|
5
|
Synthesis and antibacterial activity of novel lincomycin derivatives. IV. Optimization of an N-6 substituent. J Antibiot (Tokyo) 2017; 70:1112-1121. [PMID: 29115289 DOI: 10.1038/ja.2017.143] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2017] [Revised: 10/07/2017] [Accepted: 10/07/2017] [Indexed: 11/08/2022]
Abstract
The design and synthesis of lincomycin derivatives modified at the C-6 and C-7 positions are described. A substituent at the C-7 position is a 5-aryl-1,3,4-thiadiazol-2-yl-thio group that generates antibacterial activities against macrolide-resistant Streptococcus pneumoniae and Streptococcus pyogenes carrying an erm gene. An additional modification at the C-6 position was explored in application of information regarding pirlimycin and other related compounds. These dual modifications were accomplished by using methyl α-thiolincosaminide as a starting material. As a result of these dual modifications, the antibacterial activities were improved compared with those of compounds with a single modification at the C-7 position. The antibacterial activities of selected compounds in this report against macrolide-resistant S. pneumoniae and S. pyogenes with an erm gene were superior to those of telithromycin.
Collapse
|
6
|
Wakiyama Y, Kumura K, Umemura E, Masaki S, Ueda K, Sato Y, Hirai Y, Hayashi Y, Ajito K. Synthesis and SARs of novel lincomycin derivatives Part 5: optimization of lincomycin analogs exhibiting potent antibacterial activities by chemical modification at the 6- and 7-positions. J Antibiot (Tokyo) 2017; 71:298-317. [DOI: 10.1038/ja.2017.114] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2017] [Revised: 08/15/2017] [Accepted: 08/24/2017] [Indexed: 11/09/2022]
|
7
|
Kumura K, Wakiyama Y, Ueda K, Umemura E, Watanabe T, Yamamoto M, Yoshida T, Ajito K. Synthesis and antibacterial activity of novel lincomycin derivatives. III. Optimization of a phenyl thiadiazole moiety. J Antibiot (Tokyo) 2017; 71:ja201759. [PMID: 28676716 DOI: 10.1038/ja.2017.59] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2017] [Revised: 04/09/2017] [Accepted: 04/21/2017] [Indexed: 11/08/2022]
Abstract
Lincomycin derivatives that have a 5-(2-nitrophenyl)-1,3,4-thiadiazol-2-yl thio moiety at the 7-position were synthesized. 5-Substituted 2-nitrophenyl derivatives showed potent antibacterial activities against Streptococcus pneumoniae and Streptococcus pyogenes with erm gene. Antibacterial activities of the 4,5-di-substituted 2-nitrophenyl derivatives were generally comparable to those of telithromycin (TEL) against S. pneumoniae with erm gene and clearly superior to those of TEL against S. pyogenes with erm gene. Compounds 6 and 10c that have a methoxy group at the 5-position of the benzene ring exhibited activities comparable to TEL against Haemophilus influenzae. These results suggest that lincomycin derivatives modified at the 7-position would be promising compounds as a clinical candidate. We would like to dedicate this article to the special issue for late Professor Dr. Hamao Umezawa in The Journal of Antibiotics.The Journal of Antibiotics advance online publication, 5 July 2017; doi:10.1038/ja.2017.59.
Collapse
Affiliation(s)
- Ko Kumura
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan
| | - Yoshinari Wakiyama
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan
| | - Kazutaka Ueda
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan
| | - Eijiro Umemura
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan
| | - Takashi Watanabe
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan
| | - Mikio Yamamoto
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan
| | - Takuji Yoshida
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan
| | - Keiichi Ajito
- Pharmaceutical Research Center, Meiji Seika Pharma Co., Ltd, Yokohama, Japan
| |
Collapse
|
8
|
Wakiyama Y, Kumura K, Umemura E, Ueda K, Watanabe T, Yamada K, Okutomi T, Ajito K. Synthesis and structure–activity relationships of novel lincomycin derivatives. Part 4: synthesis of novel lincomycin analogs modified at the 6- and 7-positions and their potent antibacterial activities. J Antibiot (Tokyo) 2017; 70:888-906. [DOI: 10.1038/ja.2017.54] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2017] [Accepted: 03/20/2017] [Indexed: 11/09/2022]
|
9
|
Synthesis and antibacterial activity of novel lincomycin derivatives. II. Exploring (7S)-7-(5-aryl-1,3,4-thiadiazol-2-yl-thio)-7-deoxylincomycin derivatives. J Antibiot (Tokyo) 2016; 70:655-663. [DOI: 10.1038/ja.2016.139] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2016] [Revised: 09/25/2016] [Accepted: 10/23/2016] [Indexed: 12/15/2022]
|
10
|
Synthesis and structure-activity relationships of novel lincomycin derivatives part 3: discovery of the 4-(pyrimidin-5-yl)phenyl group in synthesis of 7(S)-thiolincomycin analogs. J Antibiot (Tokyo) 2016; 70:52-64. [PMID: 27703159 DOI: 10.1038/ja.2016.114] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2016] [Revised: 07/31/2016] [Accepted: 08/05/2016] [Indexed: 11/08/2022]
Abstract
Novel lincomycin derivatives possessing an aryl phenyl group or a heteroaryl phenyl group at the C-7 position via sulfur atom were synthesized by Pd-catalyzed cross-coupling reactions of 7(S)-7-deoxy-7-thiolincomycin (5) with various aryl halides. This reaction is the most useful method to synthesize a variety of 7(S)-7-deoxy-7-thiolincomycin derivatives. On the basis of analysis of structure-activity relationships of these novel lincomycin derivatives, we found that (a) the location of basicity in the C-7 side chain was an important factor to enhance antibacterial activities, and (b) compounds 22, 36, 42, 43 and 44 had potent antibacterial activities against a variety of Streptococcus pneumoniae with erm gene, which cause severe respiratory infections, even compared with our C-7-modified lincomycin analogs (1-4) reported previously. Furthermore, 7(S)-configuration was found to be necessary for enhancing antibacterial activities from comparison of configurations at the 7-position of 36 (S-configuration) and 41 (R-configuration).
Collapse
|